Study #2025-0536
A phase 1, first-in-human, open-label study to evaluate the safety, tolerability, pk, and preliminary anti-tumor activity of the novel oral selective CDK2/4 dual degrader NKT5097 in adults with advanced/metastatic solid tumors
MD Anderson Study Status
Enrolling
Treatment Agent
NKT5097 CDK2/CDK4 dual degrader
Description
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2 * What medical issues/symptoms do participants experience when taking NKT5097
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Uterine Carcinosarcoma
Study phase:
Phase I
Physician name:
Timothy Yap
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.